The main goal of this Myelonna SPORE program is to develop novel targeted therapies to more effectively treat patients with multiple myeloma (MM). Clinically relevant animal models are crucial for examining the in vivo efficacy of novel agents. The dedicated personnel and facilities of the Animal Models Core (Core D) provide the program with clinically relevant animal models and expertise in animal studies essential to achieving the aims ofthe Projects. Core personnel work closely with SPORE investigators to plan animal studies and to develop optimal and clinically relevant mouse models of myeloma. During the past 5 years, the Department of Lymphoma and Myeloma and M. D. Anderson Cancer Center have provided excellent conditions in terms of access to primary myeloma samples, myeloma tissue bank, interaction between clinical and translational research programs, and animal facilities for providing unique, clinically relevant samples to establish myeloma SCID and SCID-hu mouse models, which allow reproducibly engraftment of established human myeloma cell lines or primary myeloma cells freshly isolated from patients with MM, respectively. Establishment of myeloma in SCID-hu mice induces typical human MM manifestations including disease heterogeneity commonly seen in the clinic. The Animal Models Core is well suited to provide expertise and mouse models for the SPORE given that the Animal Models Core Personnel, animal facilities, and tissue banks are all located within the South Campus Research Buildings of our institution where our laboratories are concentrated. This provides a level of integration for the Core that will maximize uniformity and use of available animal models and patients'materials by SPORE investigators.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Glitza, Isabella C; Lu, Gary; Shah, Rupin et al. (2015) Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma 56:602-7
Wen, Jianguo; Tao, Wenjing; Kuiatse, Isere et al. (2015) Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. Int J Cancer 136:991-1002
Hong, Bangxing; Li, Haiyan; Zhang, Mingjun et al. (2015) p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion. Int J Cancer 136:34-43
Shi, Qiuling; Wang, Xin Shelley; Li, Guojun et al. (2015) Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer 121:1138-46
Wang, Xin Shelley; Shi, Qiuling; Williams, Loretta A et al. (2015) Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk Lymphoma 56:1335-41
Parmar, S; Kongtim, P; Champlin, R et al. (2014) Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant 49:1036-41
Chen, Zheng; Orlowski, Robert Z; Wang, Michael et al. (2014) Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood 123:2204-8
San-Miguel, Jesús; Bladé, Joan; Shpilberg, Ofer et al. (2014) Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 123:4136-42
Srkalovic, Gordan; Hussein, Mohamad A; Hoering, Antje et al. (2014) A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer Med 3:1275-83
Ocio, Enrique M; Mitsiades, Constantine S; Orlowski, Robert Z et al. (2014) Future agents and treatment directions in multiple myeloma. Expert Rev Hematol 7:127-41

Showing the most recent 10 out of 79 publications